Acrivon Therapeutics to Highlight its ACR-368 OncoSignature
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage...
Source: globenewswire.com
Predictive Precision Proteomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Predictive Precision Proteomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Predictive Precision Proteomics Today - Breaking & Trending Today
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
WATERTOWN, Mass., Sept. 19, 2023 -- Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are...
Source: marketscreener.com
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
Acrivon's Predictive Precision Proteomics platform is a proprietary, broadly applicable, next-generation precision oncology platform at the forefront of the next wave of biology-driven drug...
Source: marketscreener.com
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
WATERTOWN, Mass., March 28, 2023 -- Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors... | March 28, 2023
Source: marketscreener.com
Acrivon Therapeutics Prices $99.4M Initial Public Offering
The firm will use the funds from the IPO to advance Acrivon's lead candidate, the CHK1 and CHK2 inhibitor ACR-368.
Source: precisiononcologynews.com